The Denver-based company said that former CEO Thiry will transition to serve as executive chairman of the board, and that the announcement comes as part of a multi-year succession planning process.
Rodriguez has served as DaVita Kidney Care CEO since 2014, and held a number of other positions since joining the company in 1998. Prior to joining DaVita, Rodriguez worked for Baxter, the company said.
“I am deeply grateful for my opportunity to be a part of the DaVita journey, with thousands of teammates for whom I have immense respect and affection. We have done so many wonderful things for patients and their families. I am excited that Javier Rodriguez, with whom I have partnered for 20 years, will succeed me. The Village is in a strong position for the next chapter, and Javier is the right person to build on our foundation and take us to the next level of clinical and economic performance,” Thiry said in prepared remarks.
“On behalf of the board of directors, I thank Kent for his vision and leadership as CEO and the extraordinary culture he helped create. Under his leadership, DaVita has grown to be one of the largest and most innovative health care communities in the world with nearly 3,000 dialysis centers in 10 countries. Javier has created substantial value for the company over nearly two decades, most recently serving as CEO of the largest division of our business. The board is confident that Javier will be a strong steward for our mission and culture and lead a successful next chapter of the enterprise,” lead independent board director Peter Grauer said in a prepared statement.
“I am honored to be the next CEO of DaVita, and I greatly appreciate the confidence that both Kent and the board have placed in me. I also want to thank Kent for his leadership and continued support as executive chairman. DaVita is positioned well to execute on significant opportunities ahead and I look forward to working with the team on the next phase of our evolution to benefit our patients, teammates, physician partners and healthcare community as a whole,” Rodriquez said in a press release.
EarlySense said earlier this month that it named Matt Johnson as its new CEO, succeeding co-founder and founding CEO Avner Halperin who has led the company since its launch in 2004.
Prior to joining Woburn, Mass.-based EarlySense, Johnson served as managing director of PE firm Sowell & Co. and as CEO of health platform company CareCycle Solutions. Johnson also served as CEO of HealthBridge In-Home Care, EarlySense said.
“EarlySense has established itself as the global leader of contact-free continuous sensing and analytics technology, and, as we are accelerating our commercial growth in the U.S. and global markets, now is the time to bring in a CEO with a skill set to facilitate that growth. We are excited that Matt Johnson, an executive with formidable healthcare and economic skill, will lead our team in pursuit of our goal to become the standard of care for patient monitoring in hospitals, nursing homes and the home. Furthermore, it has been a privilege and an honor to work with Avner Halperin, who developed EarlySense from concept to its strong standing today, and we look forward to Avner’s continued contribution as a director on EarlySense’s board,” chairman Ittai Harel said in a press release.
“EarlySense has done an incredible job establishing the scientific-foundation for continuous patient monitoring in varied healthcare settings, and has forged key partnerships with some of the leading healthcare providers and suppliers. EarlySense proprietary technology is poised to impact thousands of patients’ lives, as well as reduce costs in healthcare facilities around the world. I am appreciative of the opportunity and look forward to leading this innovative company,” Johnson said in a prepared statement.
“Today, more than one million patients have enjoyed the benefit of monitoring and health analytics with EarlySense technology that empowers healthcare professionals to achieve better clinical and economic outcomes. Matt Johnson is a stellar choice to carry forward our mission of ensuring prompt care, saving lives and reducing medical costs. I look forward to being there to support Matt and the company’s continued success,” Halperin said in a prepared statement.
Sternberg has held positions including U.S. commercial head for seven therapeutic area biz units and neuroscience chief commercial officer for Shire prior to its acquisition by Takeda Pharma, the Menlo Park, Calif.-based company said.
Staple will continue with the company as its board chair, Corium said.
“I’m very excited to welcome Perry to lead Corium into the next major phase of our development. He brings years of demonstrated launch success across a variety of therapeutic areas. Perry is uniquely qualified to step into the leadership role and build out the organization to commercialize our own products, starting with our lead Corplex Donepezil candidate for Alzheimer’s patients, and help guide the development of Corium’s pipeline,” Staple said in a prepared statement.
“I am honored to be joining the Corium team at such an important point in its history, and look forward to building on its strengths in developing and manufacturing innovative transdermal products. Based on Corium’s pipeline of products in development, as well as the financial backing and deep industry expertise the company has from Gurnet Point Capital, we have a clear opportunity to accelerate the growth of the company and meet the needs of patients and their families,” Sternberg said in a press release.
Voskuil will be leaving to take up the role of senior VP and chief financial officer at The Hershey Company, Avanos Medical said.
The Alpharetta, Ga.-based company said that it has launched a search for a new chief financial officer to replace the departing Voskuil.
The FDA has tapped Pew Charitable Trusts public health program director Elizabeth Jungman as its new Office of Regulatory Policy head, according to a STAT report.
In the role, Jungman will oversee issues including drug compounding and policy, according to the report.
Jungman has previously worked closely with the federal watchdog and has been vocal in their support of a number of different controversial policies, STAT reports.
- BioRad appoints Last as COO, EVP
- Lantheus Holdings chief med officer Orlandi to retire
- Micron Solutions names Laursen as treasurer, principal accounting & financial officer
- ElectroMed adds Reeves as sales VP
- Clinical Innovations hires Rickenbaugh as biz dev, strategy VP
- Meyer Burger CCO Escher to step down